Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2010

Open Access 01-02-2010 | Review Article

Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies

Authors: G. Malviya, F. Conti, M. Chianelli, F. Scopinaro, R. A. Dierckx, A. Signore

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2010

Login to get access

Abstract

The closing of the last century opened a wide variety of approaches for inflammation imaging and treatment of patients with rheumatoid arthritis (RA). The introduction of biological therapies for the management of RA started a revolution in the therapeutic armamentarium with the development of several novel monoclonal antibodies (mAbs), which can be murine, chimeric, humanised and fully human antibodies. Monoclonal antibodies specifically bind to their target, which could be adhesion molecules, activation markers, antigens or receptors, to interfere with specific inflammation pathways at the molecular level, leading to immune-modulation of the underlying pathogenic process. These new generation of mAbs can also be radiolabelled by using direct or indirect method, with a variety of nuclides, depending upon the specific diagnostic application. For studying rheumatoid arthritis patients, several monoclonal antibodies and their fragments, including anti-TNF-α, anti-CD20, anti-CD3, anti-CD4 and anti-E-selectin antibody, have been radiolabelled mainly with 99mTc or 111In. Scintigraphy with these radiolabelled antibodies may offer an exciting possibility for the study of RA patients and holds two types of information: (1) it allows better staging of the disease and diagnosis of the state of activity by early detection of inflamed joints that might be difficult to assess; (2) it might provide a possibility to perform ‘evidence-based biological therapy’ of arthritis with a view to assessing whether an antibody will localise in an inflamed joint before using the same unlabelled antibody therapeutically. This might prove particularly important for the selection of patients to be treated since biological therapies can be associated with severe side-effects and are considerably expensive. This article reviews the use of radiolabelled mAbs in the study of RA with particular emphasis on the use of different radiolabelled monoclonal antibodies for therapy decision-making and follow-up.
Literature
1.
Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93.CrossRefPubMed
2.
Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998;317:180–1.PubMed
3.
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303–7.CrossRefPubMed
4.
Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30:36–40.PubMed
5.
Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497–502.CrossRefPubMed
6.
Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–94.CrossRefPubMed
7.
Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347–56.CrossRefPubMed
8.
Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48:54–8.CrossRefPubMed
9.
O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate, sulphasalazine and hydroxychloroquine, or a combination of these medications. New Engl J Med. 1996;334:1287–91.CrossRefPubMed
10.
Landewè RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347–56.CrossRefPubMed
11.
Choy EH, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheumatol. 1998;37:484–90.CrossRefPubMed
12.
Fan PT, Leong KH. The use of biological agents in the treatment of rheumatoid arthritis. Ann Acad Med Singapore. 2007;36:128–34.PubMed
13.
Chianelli M, D’Alessandria C, Conti F, Priori R, Valesini G, Annovazzi A, et al. New radiopharmaceuticals for imaging rheumatoid arthritis. Q J Nucl Med Mol Imaging. 2006;50:217–25.PubMed
14.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–97.CrossRefPubMed
15.
Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52–62.CrossRefPubMed
16.
Aksentijevich I, Flinn IW. Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. Cancer Control. 2002;9(2):99–105.PubMed
17.
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Nat Acad Sci. 1984;81:6851–5.CrossRefPubMed
18.
19.
Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52–62.CrossRefPubMed
20.
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522–5.CrossRefPubMed
21.
Holmes MA, Buss TN, Foote J. Conformational correction mechanisms aiding antigen recognition by a humanized antibody. J Exp Med. 1998;187:479–85.CrossRefPubMed
22.
Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn’s disease. Pharmacogenomics. 2004;5(5):479–86.CrossRefPubMed
23.
Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol. 2005;23:1105–16.CrossRefPubMed
24.
25.
Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol. 2002;13:609–14.CrossRefPubMed
26.
Weir AN, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson AD. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans. 2002;30:512–16.CrossRefPubMed
27.
Kaushik VV, Moots RJ. CDP-870 (Certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther. 2005;5(4):601–6.CrossRefPubMed
28.
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443–53.CrossRefPubMed
29.
Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine. 1995;7:251–59.CrossRefPubMed
30.
Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Eng J Med. 2006;355:704–12.CrossRef
31.
ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206–11.CrossRefPubMed
32.
Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15–25.CrossRefPubMed
33.
Barone D, Krantz C, Lambert D, Maggiora K, Mohler K. Comparative analysis of the ability of Etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion. Arthritis Rheum. 1999;42(Suppl):S90.
34.
Annovazzi A, D’Alessandria C, Caprilli R, Viscido A, Corsetti F, Parisella MG, et al. Radiolabelling of a monoclonal anti-TNF-α antibody with 99mTc: in vitro studies. Q J Nucl Med Mol Imaging. 2002;46(Suppl 1):27.
35.
Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valesini G, et al. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum. 2005;52(4):1224–26.CrossRefPubMed
36.
Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005;34(Suppl):19–22.CrossRefPubMed
37.
Rau R. Adalimumab (a fully human anti-tumour necrosis factor a monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis. 2002;61(Suppl II):70–3.
38.
39.
Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabelled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022–8.PubMed
40.
Barrera P, Oyen WJ, Boerman OC, van Riel PL. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:825–8.CrossRefPubMed
41.
Malviya G, D’Alessandria C, Lanzolla T, Lenza A, Conti F, Valesini G, et al. 99mTechnetium labelled anti-TNF-α antibodies for the therapy-decision making and follow-up of patients with rheumatoid arthritis. Q J Nucl Med Mol Imaging. 2008;52(Suppl 1(2)):13–4.
42.
43.
Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678–85.PubMed
44.
Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B-cell activation and differentiation. J Immunol. 1985;135(2):973–9.PubMed
45.
Dorner T. Rumester, G. The role of B-cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol. 2003;15:246–52.CrossRefPubMed
46.
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.PubMed
47.
48.
Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from Rituximab. Sci STKE. 2004;2004(241):30.CrossRef
49.
Stopar TG, Mlinaric-Rascan I, Fettich J, Hojker S, Mather SJ. 99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin’s lymphoma imaging agent. Eur J Nucl Med. 2006;33:53–9.CrossRef
50.
Stalteri MA, Mather SJ. Technetium-99m labelling of the antitumour antibody PR1A3 by photoactivation. Eur J Nucl Med. 1996;23:178–87.CrossRefPubMed
51.
Wang XJ, Lin BH, Yang Z, Ouyang T, Li JF, Xu B, et al. Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient. Zhonghua Zhong Liu Za Zhi (Chinese J Oncol). 2006;28(3):200–3.
52.
Malviya G, Laganà B, Milanetti F, Del Mastro C, Familiari D, Dierckx RA, et al. Use of 99m-technetium labelled Rituximab for imaging of patients with chronic inflammatory diseases. Eur J Nucl Med Mol Imaging. 2008;35(Suppl 2):S142.
53.
Pohlers D, Schmidt-Weber CB, Franch A, Kuhlmann J, Bräuer R, Emmrich F, et al. Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kB binding activity and TNF-α secretion of T cells. Arthritis Res. 2002;4:184–89.CrossRefPubMed
54.
Reddy MP, Kinney CAS, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol. 2000;164:1925–33.PubMed
55.
Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol. 2002;29:220–29.PubMed
56.
Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol. 1996;106:427–33.CrossRefPubMed
57.
Kinne RW, Becker W, Schwab J, Horneff G, Schwarz A, Kalden JR, et al. Comparison of 99Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis. Nucl Med Commun. 1993;14(8):667–75.CrossRefPubMed
58.
Kinne RW, Becker W, Schwab J, Schwarz A, Kalden JR, Emmrich F, et al. Imaging rheumatoid arthritis joints with technetium-99m labelled specific anti-CD4- and non-specific monoclonal antibodies. Eur J Nucl Med. 1994;21:176–80.CrossRefPubMed
59.
Becker W, Emmrich F, Horneff G, Burmester G, Seiler F, Schwarz A, et al. Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies. Eur J Nucl Med. 1990;17(3–4):156–9.CrossRefPubMed
60.
Bevilacqua MP. Endothelial-leukocytes adhesion molecules. Ann Rev Immunol. 1993;11:767–804.CrossRef
61.
Mason JC, Haskard DO. The clinical importance of leucocytes and endothelial cell adhesion molecules in inflammation. Vasc Med Rev. 1994;5:249–75.
62.
Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leucocyte adhesion molecule-1: an inducible receptor for neutrophils related to complement proteins and lectins. Science. 1989;243:1160–65.CrossRefPubMed
63.
Bhushan M, Bleiker TO, Ballsdon AE, Allen MH, Sopwith M, Robinson MK, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol. 2002;146:824–31.CrossRefPubMed
64.
Pober JS, Bevilacqua MP, Mendrik DL, Lapierre LA, Fiers W, Gimborn MA Jr. Two distinct monokines, interleukin 1 and tumor necrosis factor, each in dependently induce biosynthesis and transient expression of the antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986;136:1680–87.PubMed
65.
Wellicome SM, Thornhill MH, Pitzalis C, Thomas DS, Lanchbury JS, Panayi GS, et al. A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1 or lipopolysaccharide. J Immunol. 1990;144:2558–65.PubMed
66.
67.
Jamar F, Chapman PT, Harrison AA, Binns RM, Haskard DO, Peters AM. Inflammatory arthritis: imaging of endothelial cell activation with an indium-111-labelled F(ab’)2 fragment of anti-E-selectin monoclonal antibody. Radiology. 1995;194:843–50.PubMed
68.
Chapman PT, Jamar F, Keelan ET, Peters AM, Haskard DO. Use of monoclonal antibody against E-selectin for imaging endothelial activation in rheumatoid arthritis. Arthritis Rheum. 1996;39:1371–75.CrossRefPubMed
69.
Jamar F, Chapman PT, Manicourt D-H, Glass DM, Haskard DO, Peters AM. A comparison between 111In-anti-E-selectin mAb and 99Tcm-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis. Brit J Radiol. 1997;70:473–81.PubMed
70.
van der Lubbe PA, Arndt JW, Calame W, Ferreira TC, Pauwels EK, Breedveld FC. Measurement of synovial inflammation in rheumatoid arthritis with technetium-99m labelled human polyclonal immunoglobulin G. Eur J Nucl Med. 1991;18:119–23.CrossRefPubMed
71.
de Bois MH, Arndt JW, van der Velde EA, van der Lubbe PA, Westedt ML, Pauwels EK, et al. 99mTc-human immunoglobulin scintigraphy- a reliable method to detect joint activity in rheumatoid arthritis. J Rheumatol. 1992;19:1371–6.PubMed
72.
Liberatore M, Clemente M, Iurilli AP, Zorzin L, Marini M, Di Rocco E, et al. Scintigraphic evaluation of disease activity in rheumatoid arthritis: a comparison of technetium-99m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med. 1992;19:853–57.CrossRefPubMed
73.
Jamar F, Houssiau FA, Devogelaer J-P, Chapman PT, Haskard DO, Beaujean V, et al. Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. Rhematol. 2002;41:53–61.CrossRef
74.
Keelan ETM, Harrison AA, Chapman PT, Binns RM, Peters AM, Haskard DO. Imaging vascular endothelial activation: an approach using radiolabelled monoclonal antibodies against the endothelial cell adhesion molecule E-selectin. J Nucl Med. 1994;35:276–81.PubMed
75.
Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002;29:1907–13.PubMed
76.
Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, et al. A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994;57:1537–43.PubMed
77.
Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O’Laughlin R, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999;68:608–16.CrossRefPubMed
78.
Cole MS, Stellrecht KW, Shi JD, Homola M, Hsu DH, Anasetti C, et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation. 1999;68(4):563–71.CrossRefPubMed
79.
Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation. 1995;60(8):847–53.CrossRefPubMed
80.
Cole M, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells. J Immunol. 1997;159:3613–21.PubMed
81.
Trajkovic V. Nuvion Protein Design Labs. Curr Opin Investig Drugs. 2002;3(3):411–4.PubMed
82.
83.
Marcus C, Thakur ML, Huynh TV, Louie JS, Leibling M, Minami C, et al. Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3. Nucl Med Commun. 1994;15(10):824–30.CrossRefPubMed
84.
Martins FPP, Gutfilen B, De Souza SAL, De Azevedo MNL, Cardoso LR, Fraga R, et al. Monitoring rheumatoid arthritis synovitis with 99mTc-anti-CD3. Brit J Radiol. 2008;81:25–9.CrossRefPubMed
85.
Malviya G, De Vries EFJ, Dierckx RA, Signore A. Radiopharmaceuticals for imaging chronic lymphocytic inflammation. Bra Arch Bio Tech. 2007;50:1–13.
86.
Malviya G, D’Alessandria C, Trotta C, Massari R, Soluri A, Scopinaro F, et al. Radiolabeled-Visilizumab, a humanized anti-CD3 monoclonal antibody, for in vivo targeting of human CD3+ lymphocytes. Eur J Nucl Med Mol Imaging. 2008;35(Suppl 2):S142.
Metadata
Title
Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies
Authors
G. Malviya
F. Conti
M. Chianelli
F. Scopinaro
R. A. Dierckx
A. Signore
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1272-0

Other articles of this Issue 2/2010

European Journal of Nuclear Medicine and Molecular Imaging 2/2010 Go to the issue

Original Article

Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate

Focus on

Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis

Editorial Commentary

Therapeutic nuclear medicine expands to breast cancer

Guidelines

EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2

Image of the Month

Symmetrical nail bed uptake on a 99mTc-HDP bone scan in a patient with Wegener’s granulomatosis

Original Article

Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy